Phio Pharmaceuticals Corp. PHIO 深 滬
等待開盤 03-26 09:30:00 美东时间
1.26
+0.040
+3.28%
華盛通- 最 高1.28
- 今 開1.23
- 成交量 18.80万股
- 最 低 1.23
- 昨 收 1.22
- 總市值 1463.78万
- 52周最高 4.1899
- 市盈率 靜 --
- 換手率 1.62%
- 52周最低 0.8127
- 委 比 -90.87%
- 總股本 1161.73万
- 歷史最高 3118.50
- 量 比 0.57
- 振 幅 4.10%
- 歷史最低 0.8127
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b clinical study (NCT
03-23 19:17
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma Phio said Phase 1b results from its escalating-dose study of intratumoral PH-762 (NCT 06014086) in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma will
03-23 19:04
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Phio Pharmaceuticals Corp. will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series with a live presentation and Q&A on Monday, March 9, 2026 at 10:00 a.m. EDT
03-05 20:03
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms Phio Pharmaceuticals Corp. amended CEO Robert J. Bitterman’s employment agreement. The update raises his annual target bonus opportunity to 50% of base salary (from 40%) and provides 12 months of base-salary severance if he i
02-19 05:01
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
The Safety Monitoring Committee Concluded Its Planned Safety Review For All Patients Treated With The INTASYL compound PH-762 In Phio Pharmaceuticals' Phase 1b Trial, No Serious Adverse Events Or Dose-limiting Toxicities Identified
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders
02-10 20:09
Phio Pharmaceuticals Reports Positive Safety and Efficacy Results for PH-762 in Phase 1b Skin Cancer Trial
Phio Pharmaceuticals Reports Positive Safety and Efficacy Results for PH-762 in Phase 1b Skin Cancer Trial Phio Pharmaceuticals Corp. has announced the completion of a safety review by the Safety Monitoring Committee (SMC) for its lead clinical candidate, PH-762, in a Phase 1b skin cancer trial. The
02-10 20:03
Phio Pharmaceuticals meldet erfolgreiche Sicherheitsdaten für PH-762 in Phase-1b-Hautkrebsstudie
Phio Pharmaceuticals meldet erfolgreiche Sicherheitsdaten für PH-762 in Phase-1b-Hautkrebsstudie Phio Pharmaceuticals Corp. hat bekannt gegeben, dass der Sicherheitsüberwachungsausschuss (SMC) die geplante Sicherheitsüberprüfung für alle mit dem Wirkstoff PH-762 behandelten Patienten in einer Phase-
02-10 20:03
Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced
01-20 22:35
Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results
Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage
2025-12-23 21:47
